CPRR04-EFC4690/TROG 02.02 – HEADSTART
"Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer"
The TROG 07.03 RadioHum trial evaluated the impact of humidification on mucositis in patients treated for head and neck cancer. Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer.
Although it did not demonstrate a significant difference between the mucositis experienced by the two groups, the results show that humidification can play a role in reducing symptoms during radiation therapy for head and neck cancer. On average, patients who received humidification spent less time in the hospital to manage side effects. The return of eating patterns to close to normal was also significantly higher at three months after radiation therapy in the group using humidifiers. The secondary analyses are currently underway.
Earlybird registration closes 26 January.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292